Ani Pharmaceuticals Inc (ANIP) Stock Price & Analysis
Ani Pharmaceuticals Inc (ANIP) fell 1.40% to USD 70.23 as of September 8, 2026 at 23:01 UTC, according to Nexqual real-time market data.
ANIP last closed at USD 70.23; the session ranged USD 70.16–71.84 on volume of 253,499 shares. Market capitalization is —, with a 52-week range of USD 70.15–99.5 (NGM). Source: Nexqual, September 8, 2026 at 23:01 UTC.
Key Statistics (as of September 8, 2026 at 23:01 UTC)
| Price | USD 70.23 |
|---|---|
| Change | ▼ 1.40% (down) |
| Previous Close | USD 70.23 |
| Open | USD 70.23 |
| Day Range | USD 70.16 – 71.84 |
| 52-Week Range | USD 70.15 – 99.5 |
| Volume | 253,499 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (ANIP)
Nexqual's technical model rates ANIP "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of September 8, 2026 at 23:01 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.53 (neutral) |
| vs SMA50 | Below (USD 78.31) |
| MACD | -1.97 (negative) |
From Ani Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") approved the Company's Supplemental New Drug Application ("sNDA") for Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis ("MS") and rheumatoid arthritis ("RA"), in addition to excess urinary protein due to nephrotic syndrome.
- Any change in one of our API suppliers generally is required to be approved by the FDA through a prior approval supplement ("PAS").
- From time to time, we have experienced temporary disruptions in the supply of certain of such imported API due to FDA inspections and customs delays.
- Generally, prescription pharmaceutical products distributed in the U.S., whether branded or generic, must be approved by the FDA through the NDA, 505(b)(2) New Drug Application ("505(b)(2) NDA") or ANDA processes.
Partnerships
- In the wake of the executive orders and related executive initiatives, a number of pharmaceutical manufacturers have announced direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc. | USD 13.5 | ▼ 3.71% |
| AMPH | Amphastar Pharmaceuticals, Inc. | USD 22.93 | ▼ 3.82% |
| ANIK | Anika Therapeutics Inc. | USD 21.04 | ▲ 0.19% |
| COLL | Collegium Pharmaceutical, Inc. | USD 23.37 | ▼ 1.39% |
| PCRX | Pacira BioSciences, Inc. | USD 25.87 | ▼ 2.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 23:01 UTC. This page is informational and not investment advice.